LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$65.46 USD
+2.47 (3.92%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.45 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth D Momentum D VGM
Brokerage Reports
0 items in cart
LeMaitre Vascular, Inc. [LMAT]
Reports for Purchase
Showing records 101 - 120 ( 188 total )
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
2Q19 Recap - Upside Results Appear Priced In (Pending Acquisitions)
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
1Q19 Recap - Acquisitions Appear the Near-Term Driver
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
We are placing shares Under Review, and transferring coverage to due to the departure of the covering analyst
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
We are transferring coverage, placing Under Review, and removing PT''s and estimates
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Transferring coverage with a Neutral rating, $39/share price target
Provider: Roth Capital Partners, Inc.
Analyst: SOLOMON D
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
2Q18 Recap - In Line Quarter, Near- Term Acquisition?
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Growth Story Intact; Resuming with a Buy Rating, $38 PT
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Healthcare - Coverage Update - Healthcare Sector
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
We are placing shares of LMAT Under Review, and transferring coverage to Scott Henry, CFA due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
We are placing shares of LMAT Under Review, and transferring coverage to Scott Henry, CFA due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.